Biotech Acquisition Co (Biotech Acquisition Co) Change In Receivables : $0.00 Mil (TTM As of Sep. 2022)

View and export this data going back to 2021. Start your Free Trial

What is Biotech Acquisition Co Change In Receivables?

Biotech Acquisition Co's change in receivables for the quarter that ended in Sep. 2022 was $0.00 Mil. It means Biotech Acquisition Co's Accounts Receivable stayed the same from Jun. 2022 to Sep. 2022 .

Biotech Acquisition Co's change in receivables for the fiscal year that ended in Dec. 2021 was $0.00 Mil. It means Biotech Acquisition Co's Accounts Receivable stayed the same from Dec. 2020 to Dec. 2021 .

Biotech Acquisition Co's Accounts Receivable for the quarter that ended in Sep. 2022 was $0.00 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Biotech Acquisition Co's liquidation value for the three months ended in Sep. 2022 was $-13.20 Mil.

Biotech Acquisition Co Change In Receivables Historical Data

The historical data trend for Biotech Acquisition Co's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biotech Acquisition Co Change In Receivables Chart

Biotech Acquisition Co Annual Data

Trend

Dec20

Dec21

Change In Receivables

Biotech Acquisition Co Quarterly Data
	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22
Change In Receivables	Get a 7-Day Free Trial				-	-	-	-	-

Biotech Acquisition Co Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Sep. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

Biotech Acquisition Co (NAS:BIOT) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Biotech Acquisition Co's Days Sales Outstanding for the quarter that ended in Sep. 2022 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	0	/	0	*	91
=

2. In Ben Graham's calculation of liquidation value, Biotech Acquisition Co's accounts receivable are only considered to be worth 75% of book value:

Biotech Acquisition Co's liquidation value for the quarter that ended in Sep. 2022 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	0.013	-	13.215	+	0.75 * 0	+	0.5 * 0
=	-13.20

Biotech Acquisition Co Change In Receivables Related Terms

Thank you for viewing the detailed overview of Biotech Acquisition Co's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Biotech Acquisition Co (Biotech Acquisition Co) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Financial Services » Diversified Financial Services » Biotech Acquisition Co (NAS:BIOT) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

N/A

Address

545 West 25th Street, 20th Floor, New York, NY, USA, 10001

Website

Biotech Acquisition Co is a blank check company.

Executives

Albert F Hummel	director, officer: Chief Investment Officer	PO BOX 3407, RANCHO SANTA FE CA 92067
Biotech Sponsor Llc	10 percent owner	545 W. 25TH ST., 20TH FLOOR, NEW YORK NY 10001
Bruno Montanari	director	545 WEST 25TH STREET, 20TH FLOOR, NEW YORK NY 10001
Ivan Jarry	officer: Chief Operating Officer	545 WEST 25TH STREET, 20TH FLOOR, NEW YORK NY 10001
Paul Bernard	director	545 WEST 25TH STREET 20TH FL, NEW YORK NY 10001
Aaron Kim	director	545 WEST 25TH STREET 20TH FL, NEW YORK NY 10001
Michael Schleifer	director, 10 percent owner, officer: Chief Executive Officer	545 WEST 25TH STREET 20TH FLOOR, NEW YORK NY 10001
Thomas Fratacci	officer: CFO & Treasurer	545 WEST 25TH STREET, 20TH FLOOR, NEW YORK NY 10001